Last reviewed · How we verify

NCT05794217

A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives

Recruiting now Last updated 6 December 2024
What this trial tests

trial testing This is a non-interventional study in Rare Diseases in 20,000 participants. Currently enrolling.

Timeline
28 September 2022
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorSanguine Biosciences
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment20,000
Start date28 September 2022
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Sanguine Biosciences

Who can join

Adults 18 to 89, any sex, with Rare Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To collect, preserve, and distribute annotated leukopak biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions. This protocol will be utilized to collect research grade products that are not meant for transfusion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of This is a non-interventional study

Trials testing the same drug.

Other recruiting trials for Rare Diseases

Currently open trials in the same condition.

Other Sanguine Biosciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing